Shining a Light on Lung Cancer: The Promise of Abenacianine

In this ONCOLife exclusive, John Santini, CEO of Vergent Bioscience, reveals how intraoperative molecular imaging with abenacianine (VGT-309) is reshaping the future of lung cancer surgery. We dive into the groundbreaking VISUALIZE Phase 2B study, which showed that abenacianine identified tumors missed by standard methods in 45% of cases—enabling more complete, accurate, and tissue-sparing resections. You can follow this interview on LinkedIn by this link:>>>

John Santini also shares how this cutting-edge innovation is driving progress in minimally invasive and robotic-assisted surgery, and what’s on the horizon as Vergent moves toward a pivotal Phase 3 trial.

Some of the key topics in this interview include:

✔️ How abenacianine improves tumor visualization in real time
✔️ The clinical impact of identifying hidden or incomplete tumor margins
✔️ Integration of this imaging agent into existing surgical workflows
✔️ What the Phase 2B results mean for the future of oncologic surgery
✔️ Plans for Phase 3 and broader applications beyond lung cancer